Search The Medical Knowledge Base

Drug Details

TAMPOVAGAN

• Drug Class Description
  Oestrogens.
• Generic Name
  Diethylstilbestrol [stilboestrol], lactic acid
• Presentation
  Pessaries, diethylstilbestrol 0.5 mg , lactic acid 5%.
• Description
  Pessaries.
• Indications
  Postmenopausal vaginitis.
• Adult Dosage
  2 high into the vagina at night for 2 - 3 weeks.
• Child Dosage
  Not recommended.
• Contra Indications
  

  Cancer of breast, genital tract or other oestrogen-dependent carcinoma, undiagnosed vaginal bleeding or endometriosis. Active thrombophlebitis or thromboembolic disorders. Severe cardiac, hepatic or renal disease. Dubin-Johnson or Rotor syndromes. Pregnancy, lactation.

• Special Precautions
  

  History or increased risk of thromboembolic disorders. Mild chronic liver disease; monitor liver function every 8 to 12 weeks. Closely monitor patients with cholelithiasis, otosclerosis, migraine, multiple sclerosis, epilepsy, diabetes, sclerosis, epilepsy, hypertension, porphyria, uterine fibroids, tetany.

  Examine blood pressure, pelvic organs and breasts (particularly those with fibrocystic disease of the breast or a family history of breast cancer) before and regularly during treatment. If breakthrough bleeding is persistent, perform endometrial assessment, which may include biopsy.

• Interactions
  Liver enzyme inducing drugs.
• Adverse Drug Reactions
  

  GI upset, nausea, vomiting, weight gain, breast tenderness and enlargement, breakthrough bleeding, headache, dizziness, impaired liver function, cholestatic jaundice, epistaxis, migraine, thromboembolic disorders, exacerbation of varicose veins, increased blood pressure, transient erythema, generalised pruritus.

  REASONS FOR IMMEDIATE DISCONTINUATION OF TREATMENT: Occurence of migraine-type headaches for the first time, frequent severe headaches, acute visual disturbances, signs of thrombophlebitis or thromboembolism, or any other possible prodromal symptoms of vascular occlusion. Rise in blood pressure. Jaundice. Pregnancy. Discontinue six weeks before major elective surgery and during immobilisation entailing risk of thrombosis.